Jubilant Pharmova Peer Comparison

Jubilant Pharmova Ltd. shows moderate revenue growth and decent profitability metrics compared to its peers in the pharmaceuticals sector, though it has the highest PE ratio, indicating potential overvaluation. Companies like Cipla and Dr. Reddy's stand out for their profitability and growth, while others like Divi's Laboratories face challenges with growth despite high profitability metrics. Overall, Jubilant Pharmova is positioned as a moderate growth player in a competitive landscape.

• • Jubilant Pharmova has moderate revenue growth (6.7% YoY) but high PE ratio (494.25).
• • Cipla and Dr. Reddy's lead in profitability measures with strong ROE and margins.
• • Divi's Laboratories, despite high EBITDA margins, has poor revenue growth and EPS trajectory.
• • Sun Pharma and Divi's show strong profitability but also higher valuations.

• • Cipla Ltd.: Leads in profitability metrics with a PE of 23.73 and strong revenue growth at 13.28% YoY.
• • Dr. Reddy's Laboratories Ltd.: High ROE (21.76%) and strong EPS growth (68.07) make it a top performer.
• • Mankind Pharma Ltd.: Significant revenue growth (18.12% YoY) and solid profitability metrics.